Atlantanews Online

The Metastatic Merkel Cell Carcinoma market size is anticipated to increase during the study period (2017-2030) in the 7MM

 Breaking News
  • No posts were found

The Metastatic Merkel Cell Carcinoma market size is anticipated to increase during the study period (2017-2030) in the 7MM

August 27
14:06 2021
The Metastatic Merkel Cell Carcinoma market size is anticipated to increase during the study period (2017-2030) in the 7MM
Metastatic Merkel Cell Carcinoma Market
DelveInsight’s Metastatic Merkel Cell Carcinoma market report thoroughly explains Metastatic Merkel Cell Carcinoma, historical and projected epidemiology, and Metastatic Merkel Cell Carcinoma market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan).

DelveInsight’s Metastatic Merkel Cell Carcinoma market report thoroughly explains the Metastatic Merkel Cell Carcinoma, historical and forecasted epidemiology, and the Metastatic Merkel Cell Carcinoma market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan). The Metastatic Merkel Cell Carcinoma market report also proffers an analysis of the current Metastatic Merkel Cell Carcinoma treatment practice/algorithm, Metastatic Merkel Cell Carcinoma market dynamics, and unmet medical needs.

Some of the Important Findings from the Metastatic Merkel Cell Carcinoma Market Report

  • According to the “Skin Cancer Foundation,” Merkel Cell Carcinoma (MCC) is 40 times rarer than melanoma, with 1case per 130,000 people in the United States.

  • According to the National Organization for Rare Disorders, approximately 60% of MCC tumors occur in men. In the last 15 years, the incidence in the United States has tripled, and it can be fatal for one-third of those affected.

  • Various pharmaceutical companies such as Morphogenesis, NantKwest, Kartos Therapeutics, Incyte Corporation, and others are involved in developing effective therapies for Metastatic Merkel Cell Carcinoma.

  • Various immunotherapies such as Nivolumab + Ipilimumab, INCMGA00012, haNk and aNK cell therapies, IFx-Hu2.0, and others are being developed as monotherapy as well as adjuvant therapies to treat the advanced stage Metastatic Merkel Cell Carcinoma.

  •  aNk (NK92) cell therapy developed by NantKwest is the lead immunotherapy for Merkel Cell Carcinoma in Stages IIIB and IV, and it has been designated as an orphan drug by the FDA.

  • Nivolumab is being developed by Bristol-Myers Squibb as a neoadjuvant therapy for resectable Merkel cell carcinoma. Currently, it is being tested in Phase II clinical trials along with Ipilimumab, and radiation therapy for Metastatic Merkel Cell Carcinoma.

  • Morphogenesis is developing the IFx-Hu2.0 Vaccine for the treatment of Cell Carcinoma.

To know about the different stages of metastatic merkel cell carcinoma, request for sample @ Metastatic Merkel Cell Carcinoma Market Outlook

The Metastatic Merkel Cell Carcinoma market report covers current treatment practices, emerging drugs, individual therapies’ Metastatic Merkel Cell Carcinoma market share, and current and forecasted Metastatic Merkel Cell Carcinoma market size from 2017 to 2030, segmented by seven major markets.

Metastatic Merkel Cell Carcinoma: Overview

Merkel Cell Carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous neoplasm with a variable clinical course. It is a dermal-based lesion composed of monotonous small round cells with scant cytoplasm that is frequently difficult to distinguish from small round cell tumors, metastatic small cell carcinoma, blastic hematologic malignancies, and melanoma. Merkel Cell Carcinoma has a proclivity to grow rapidly and metastasize (spread) at an early stage. It usually spreads to nearby lymph nodes first, and then to lymph nodes or skin in distant parts of the body, such as the lungs, brain, bones, or other organs.

Metastatic Merkel Cell Carcinoma Epidemiology Segmentation

The Metastatic Merkel Cell Carcinoma report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:

  • Merkel Cell Carcinoma Total Incident Population

  • Metastatic Merkel Cell Carcinoma Incident Population

  • Metastatic Merkel Cell Carcinoma Gender-Specific Cases

  • Metastatic Merkel Cell Carcinoma Diagnosed and Treatable Cases

Metastatic Merkel Cell Carcinoma Treatment Landscape

Metastatic Merkel Cell Carcinoma treatment is mainly based on the stage of the disease and the patient’s overall health. Along with surgical excision, the primary treatments for Merkel Cell Carcinoma are radiation and chemotherapy. Apart from these, some FDA-approved drugs such as Bavencio (Avelumab) and Keytruda (Pembrolizumab) are also used for advanced or Metastatic Merkel Cell Carcinoma treatment.

Metastatic Merkel Cell Carcinoma Market

Increasing disease prevalence, disease awareness, and promising emerging pipeline therapies such as Nivolumab + Ipilimumab, INCMGA00012, haNk, and aNK cell therapies, and others by key companies including Morphogenesis, NantKwest, Kartos Therapeutics, and others will drive the Metastatic Merkel Cell Carcinoma market growth during the forecast period (2020-30).

For further information on market impact by therapies, visit Metastatic Merkel Cell Carcinoma Drug Market Size

Metastatic Merkel Cell Carcinoma Pipeline Therapies and Key Companies 

  • Nivolumab: Bristol-Myers Squibb

  • INCMGA00012: Incyte Corporation

  • NK92: NantKwest

  • IFx-Hu2.0: Morphogenesis

 Table of Contents

1.

Report Introduction

2.

Executive Summary

3.

SWOT Analysis

4.

Metastatic Merkel Cell Carcinoma Market Overview at a Glance

5.

Disease Background and Overview: Metastatic Merkel Cell Carcinoma 

6.

Metastatic Merkel Cell Carcinoma Epidemiology and Patient Population  

7.

Merkel Cell Carcinoma: Country-Wise Epidemiology

8.

Metastatic Merkel Cell Carcinoma Treatment & Medical Practices 

9.

Metastatic Merkel Cell Carcinoma Marketed drugs

10.

Patient Journey

11.

Metastatic Merkel Cell Carcinoma Key Emerging Therapies

12.

Attribute Analysis

13.

Metastatic Merkel Cell Carcinoma: Market Size

14.

7MM Metastatic Merkel Cell Carcinoma: Country-Wise Market Analysis

15.

Metastatic Merkel Cell Carcinoma Market Access and Reimbursement

16.

Metastatic Merkel Cell Carcinoma Market Drivers

17.

Metastatic Merkel Cell Carcinoma Market Barriers

18.

Appendix

19.

Report Methodology

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Metastatic Colorectal Cancer Market

Get a comprehensive analysis of Metastatic Colorectal Cancer pipeline therapies and key companies such as Array Biopharma, Pfizer, Merck, Bristol-Myers Squibb, Eli Lilly, Taiho Oncology, Amgen, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/